Invivyd (NASDAQ:IVVD) Insider Sells $33,123.12 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 20,964 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total value of $33,123.12. Following the completion of the transaction, the insider directly owned 107,717 shares in the company, valued at $170,192.86. This represents a 16.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Julie Green also recently made the following trade(s):

• On Tuesday, February 17th, Julie Green sold 19,663 shares of Invivyd stock. The stock was sold at an average price of $1.54, for a total value of $30,281.02.

Invivyd Stock Performance

Shares of IVVD opened at $1.55 on Friday. Invivyd, Inc. has a 52-week low of $0.46 and a 52-week high of $3.07. The business’s 50 day moving average price is $2.16 and its two-hundred day moving average price is $1.76. The firm has a market cap of $361.34 million, a PE ratio of -3.30 and a beta of 0.60.

Institutional Investors Weigh In On Invivyd

Hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. raised its holdings in shares of Invivyd by 190.6% in the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after acquiring an additional 71,485 shares during the last quarter. AQR Capital Management LLC increased its holdings in Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after purchasing an additional 391,617 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after purchasing an additional 28,146 shares in the last quarter. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Invivyd in the second quarter worth approximately $27,000. Finally, Marshall Wace LLP purchased a new stake in shares of Invivyd in the second quarter worth approximately $158,000. 70.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. HC Wainwright upped their price objective on shares of Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, October 31st. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. Finally, D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.